Luminescent oxygen channeling immunoassay

In order to avoid the described problems, antibody-based assays have been developed. As mentioned above, usually a primary antibody recognizes the modification, which in turn is then quantitated. One of these approaches is based on the technology of AlphaScreen (Amplified luminescent Proximity Homogeneous Assay) [51, 52], also known as luminescent oxygen channeling immunoassay (LOCI) [53], a method that can be used to study protein-protein interactions in general. In this case the enzymatic transfer of acetyl groups to a histone peptide is determined. 

Ullman, E.F., Kirakossian, H., Singh, S., Wu, Z.P., Irvin, B.R., Pease, J.S., Switchenko, A.C., Irvine, J.D., DafForn, A., Skold, C.N. et al. (1994) Luminescent oxygen channeling immunoassay measurement of particle binding kinetics by chemiluminescence. Proceedings of the National Academy of Sciences of the United States of America, 91, 5426-5430. 

Ullman, E.F. et al. 1994. Luminescent oxygen channeling immunoassay measurement of particle binding kinetics by chemiluminescence. Proc. Natl. Acad. Sci. USA 91, 5426-5430. 

UUman EF, Kirakossian H, Singh S, Irvin BR, Irvine JD, Wagner DB. Luminescent oxygen channeling immunoassay (LOCI) for human thyroid stimulating hormone. In Campbell AK, Kricka LJ, Stanley PE eds, Bioiuminescence and chemiluminescence. Fundamentals and applied aspects. Chichester Wiley, 1994 6-19. 

The Amplified Luminescent Proximity Homogeneous Assay (AlphaScreen ) developed by BioSignal, is a bead-based, non-radioactive assay technology. It uses the principle of luminescent oxygen channeling, which was first described in 1994 by Ullman [173], who two years later demonstrated a broad spectrum of applications for such immunoassays [174]. This principle senses the proximity of two beads, a donor and an acceptor bead, which is mediated by the interaction of molecules on the surfaces of the two beads. 

---